Valora Therapeutics, Inc.
Valora Therapeutics is developing AbLec™ multispecific antibodies and T-Lec™ T cell engagers — antibody-engineering platforms that decoy the glyco-immune checkpoint to create best-in-class therapeutics for cancer and autoimmune disease.
Funding history
About Valora Therapeutics, Inc.
How much funding has Valora Therapeutics, Inc. raised?
Valora Therapeutics, Inc. has raised $13.0M in total funding. The most recent round was Seed.
Where is Valora Therapeutics, Inc. headquartered?
Valora Therapeutics, Inc. is headquartered in La Jolla, CA.
What does Valora Therapeutics, Inc. do?
Valora Therapeutics is developing AbLec™ multispecific antibodies and T-Lec™ T cell engagers — antibody-engineering platforms that decoy the glyco-immune checkpoint to create best-in-class therapeutics for cancer and autoimmune disease.
What problem does Valora Therapeutics, Inc. solve?
Cancer immunotherapies like PD-1/PD-L1 checkpoint inhibitors only work for a minority of patients because many tumors evade immune attack by cloaking themselves in sialic acid-rich glycans (the glyco-immune checkpoint).
What's Valora Therapeutics, Inc.'s solution?
Valora is developing multispecific AbLec antibodies and T-Lec T cell engagers that decoy the glyco-immune checkpoint to remove this immunosuppressive shield and drive stronger immune killing of cancer cells.
What makes Valora Therapeutics, Inc. different?
Its proprietary AbLec/T-Lec platform, invented by Dr. Jessica Stark in Dr. Carolyn Bertozzi's Stanford lab, is built specifically to target the glyco-immune checkpoint, a mechanism the company says prior therapies don't address.
What makes Valora Therapeutics, Inc. notable?
Co-founded by Nobel Prize-winning chemist Carolyn Bertozzi (2022 Nobel Prize in Chemistry) as scientific founder; the company raised a $30 million seed round in 2024.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.